Navigation Links
Blue Belt Technologies kondigt eerste Amerikaanse verkoop aan van het NavioPFS-operatiesysteem
Date:1/31/2013

ndeling die op exacte wijze kan worden herhaald. Precision Freehand Sculpting, de ondersteunende technologie achter de handbedieningstechniek van de NavioPFS, is de volgende stap in orthopedische, door robots geassisteerde apparatuur, waarbij het belang van de chirurg in door computers geassisteerde procedures nogmaals wordt onderstreept.

"We zijn er trots op om deze mijlpaal aan te kunnen kondigen, slechts zes weken nadat we in december 2012 goedkeuring hebben ontvangen van de FDA. Community Regional en Dr. Lester zijn geweldige partners bij het onder de aandacht brengen van de capaciteiten van het NavioPFS-systeem bij Amerikaanse patiënten en klanten," aldus Eric B. Timko , President en CEO van Blue Belt Technologies. "Deze eerste bestelling bevestigt nogmaals onze veeleisende verkoopdoelstellingen voor de Verenigde Staten dit jaar, nu het bedrijf zich richt op het beschikbaar maken van het NavioPFS-systeem in de Verenigde Staten en Europa."

Blue Belt Technologies, Inc.

Blue Belt Technologies, Inc. werkt aan de nieuwe generatie 'slimme' chirurgische instrumenten met precisierobotica voor gebruik in orthopedische ingrepen en later andere chirurgische velden, waaronder neurochirurgie, wervelkolomaandoeningen en otorinolaryngologie (ORL). Het NavioPFS-systeem van het bedrijf maakt gebruik van gepatenteerde technologie om nauwkeurige robothandelingen voor chirurgen beschikbaar te maken via een intelligent, draagbaar, door een computer geassisteerd instrument voor het snijden van bot. Dankzij het NavioPFS-systeem beschikt de chirurg over extra veiligheid en meer nauwkeurigheid bij het uitvoeren van vormgevingstaken van botten met behulp van minimaal invasieve insnijdingen.


'/>"/>
SOURCE Blue Belt Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Blue Belt Technologies gibt ersten US-Auftrag für das chirurgische NavioPFS System bekannt
2. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
3. Life Technologies trägt zur Identifizierung von 20.000 menschlichen Überresten aus Massengräbern in Libyen bei
4. Life Technologies ayuda a identificar 20.000 restos humanos encontrados en fosas comunes en Libia
5. Life Technologies va aider à identifier jusquà 20 000 restes humains trouvés dans des fosses communes en Libye
6. Life Technologies to Help Identify up to 20,000 Human Remains Found in Libyas Mass Graves
7. Solta Medical to Acquire Sound Surgical Technologies
8. Life Technologies Establishes International Influenza Network
9. Medisafe 1 Technologies Announces the Ex-Dividend Date on April 30 2013, Record Date on May 3 2013 and the Payment Date on May 6 2013
10. Masimo Showcases Advanced, Noninvasive Patient Monitoring Technologies at Arab Health
11. FCS Express Compatible with Life Technologies Tali Image Based Cytometer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
(Date:7/31/2014)... 31, 2014 Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... initiated the development of its lead molecule, Anatabine Citrate, ... has selected Quotient Clinical, The Translational Pharmaceutics Company, based ... to run its early development programs. The ... by the end of the third quarter with the ...
Breaking Medicine Technology:Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
... 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced,follow-up ... of GVAX immunotherapy,for pancreatic cancer which was ... Center. The trial enrolled 60 patients with,operable ... of their tumor and adjuvant radiation and,chemotherapy. ...
... 2002 , CHICAGO/DARMSTADT, Germany, June 4, 2007 – ... the American Society of,Clinical Oncology (ASCO) annual meeting ... patients with newly diagnosed,glioblastoma – a particularly aggressive ... integrin inhibitor targeting the,tumor and its vasculature. , ...
Cached Medicine Technology:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 2Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 3Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 4Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 5Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
(Date:7/31/2014)... A program for anyone looking to experience weight ... of Colorado Anschutz Health and Wellness Center (AHWC) ... transformation program. , “Extreme Weight Loss: Destination Boot ... an evidenced-based program inspired by the unscripted series “Extreme ... season, the show has participants spending their first three ...
(Date:7/31/2014)... Dr. Parsa Mohebi presented his groundbreaking ... enthusiastic audience of international hair restoration surgeons. His technique ... appearance of a patient’s hair transplant scar. Patients are ... minimally detectable in most cases. , The doctor ... method of donor wound closure known as Trichophytic Closure, ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 You’re having a ... why have you suddenly developed chills and fever, headache, stiff ... you suspect a flu-like illness, it could actually be the ... Your risk of developing Lyme is greater than you might ... new cases occurred in the U.S. annually. But the Centers ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 According ... Philadelphia Business Journal , Endo International, one of several ... settle thousands of transvaginal claims for $830 million (in ... Liability Litigation (MDL No. 2325). Melinda Helbock, Founder of ... she agrees with the settlement and is pleased to ...
(Date:7/31/2014)... CO (PRWEB) July 31, 2014 LDM ... new eDiscovery pricing model that is simplified and predictable ... any size. As a leading international provider of ... government agencies it has become glaringly apparent that both ... unpredictable ballooning eDiscovery budgets and the complex pricing structure ...
Breaking Medicine News(10 mins):Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 3Health News:Novel Technique in Wound Closure Delivers More Discreet Results in Hair Transplant Patients 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 3Health News:San Diego Product Liability Firm Provides Commentary on the Latest Developments in Transvaginal Mesh Litigation 2Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2
... resident Daniel Alford, MD, an associate professor of medicine ... in the General Internal Medicine Department at Boston Medical ... Abuse Prevention and Treatment Division with the Boston Public ... nation to receive the Nyswander-Dole Award. The award was ...
... ViroPharma Incorporated,(Nasdaq: VPHM ) reported today its financial results for ... since June 30, 2007 include:, Clinical:, -- Patient enrollment ... in liver transplant patients; -- Patient enrollment continued ... stem cell transplant patients; study enrollment expanded to ...
... Inc.,(Pink Sheets: HRAL) announced that it has received additional ... International, Inc.,(NYSE: WMT ), to open their ninth ... Wal-Mart Store #3195 located at 1070 Major,Mackenzie Drive in ... #7 Unit Y006A in Markham will both officially open ...
... Revenue and EPS Guidance; Provides Preliminary ... 2008 Guidance ... AM ET, BATON ROUGE, La., Oct 30 Amedisys, Inc.,(Nasdaq: AMED ... reported its financial results for the,third quarter ended September 30, 2007: Three-Month ...
... FREISING-WEIHENSTEPHAN, Germany, October 30 Pieris ... Netherlands) today,announced the commencement of a ... for G-Protein Coupled Receptors (GPCRs) and ... has pioneered Anticalins(R) as next generation ...
... Inc. (NYSE: CRY ),a biomaterials, medical device and ... been named vice president, clinical research,effective October 29, 2007. ... of CryoLife Europa, Ltd., based in the U.K., since ... has held several positions with,the Company including project director ...
Cached Medicine News:Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 3Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 4Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 5Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 6Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 7Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 8Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 9Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 10Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 2Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 3Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 2Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 3Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 4Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 5Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 6Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 7Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 8Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 9Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 10Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 11Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 12Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 13Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 14Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 15Health News:Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology 2Health News:Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology 3Health News:CryoLife Announces Additions to Management Team 2
... The TheraSeed® Pd-103 implant is a ... and remarkable visibility that makes TheraSeed® treatment ... You can be confident that every TheraSeed® ... management services which is required by clinicians ...
... BrachyStar® Needle is designed to help you ... clinically effective brachytherapy procedure. All needles are ... and polished surfaces for smooth entry and ... and sizes assures an ideal match with ...
... is a combination of innovative design, consistently ... BrachySource I-125 implant an ideal choice for ... that every BrachySource I-125 implant order is ... is required by clinicians who must meet ...
... temporary internal drainage from the ureteropelvic junction ... stricture. The segment with no sideports prevents ... preventing ingrowth of the ureteral wall to ... Intended for one-time use. CAUTION: Periodic evaluation ...
Medicine Products: